Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why not assume timeline of trail result release hasn't changed if no mention was made. Glad there is nervous nellies at this juncture. Remember how confident everyone was that Brexit would never happen? Manuso, Lippa and Margolis can take the ball across the goal line whereas old management could only manage fumbles and touchbacks all the while collecting paychecks. Too many still living in the past. If you see my past posts I was critical of old management and even new AT FIRST.
But "It's a new dawn." By the time all test results are out, reverse split is done, and NASDAC listings done the lions share of the profit will go to the bold. Plenty of burned old longs will sell, and those without shares will move on to another message board and wonder why they missed out on yet another block buster drug in early development.
Go Manuso! Timeline holds for trail results. This old dog will hunt!
Re waiting. Good move. No funding equals no trial.
Re waiting. Good move. No funding equals no trial.
Re waiting. Good move. No funding equals no trial.
IMHO funding RSPI will be the ultimate test for Margolis, Lippa and company. When you've p.o.'ed shareholders, analysts, creditors, your landlord, and the FDA it takes a little more than a name change and some promising trial hocus pokus to convince people to shell out more bucks. Judging from their past successes, if anyone can do it its these guys. They could sell sand to a Bedouin and get top dollar for every grain.
A reverse split/recap makes sense and is long overdue. Margolis and Lippa have done it in the past. That's why I'm still holding. IMHO wqe should see some action by the fall as we near completion of the government funded trial. Would be a real change if good trial results actually helped this star-crossed company.
Lets get it started in here. Time to once again dip into the Lippa Family Trust.
Come on people, lets get together some money and boogie.
Kudos to management for getting FDA hold lifted. Much better than stuffing FDA letters in your desk drawer and whining about R&R trying to steal your company and how tough things are in the big city where no one wants to play fair.
Funding. That's the rub, eh. We'll know it's on us cause in the days before it's announced they'll be a huge sucking sound as insiders and their little parasites jostle to sell what they can in advance.
That being said, multiple trials are better than none.
Once the financings, reverse splits, and trials are complete who knows, maybe the return of Dr. Tran (or someone like him) to the fold. THAT would signal somethings really brewing in the lab.
Haysaw. Re: stolen line.
Was hoping no one noticed.
This is a zombie stock for sure.
RespireRx maybe should be ExpireRx since the CX-1739 trail appears to be stillborn.
Also wonder if Manuso wants his money back from Lippa/Margolis, since they must have
known of the extent of the artifact issues from the Stoll days. Wouldn't want to be in their shoes right now trying to raise "non-dilutive" financing.
Maybe the Chinese prefer companies that have proven products, requisite governmental approval, sound financials, and cutting edge technology.
Ilumina and Novogene team up to develop NGS diagnostic system for China
Dec 14 2015, 12:37 ET | By: Douglas W. House, SA News Editor
Beijing-based Novogene and Ilumina (ILMN +0.1%) enter into a collaboration agreement to jointly develop a user-friendly diagnostic system based on next-generation sequencing (NGS) technology for clinical prenatal DNA and oncology testing in the Chinese market.
Ilumina will leverage its expertise in sequencing systems and Novogene will leverage its advanced clinical application development capabilities. Specifically, Novogene will provide its nucleic acid extraction, library preparation and data analysis software while Ilumina will provide NGS instrumentation components and related reagents.
Financial terms of the partnership are undisclosed.
...considering what happened with CX717...
Agreed. Thanks again for your efforts on behalf of the long-suffering posters on this board.
We will most likely hear something after they've crafted their official response to the FDA. The hope
being that it is a technical issue with how the trial has been constructed, and not something
ominous enough to be locked in Dr. Lippa's desk drawer, next to Dr. Stoll's infamous FDA letter that torpoedoed so many hopes and dreams.
Bravo gfp. Comparing our boys to Stoll/Varney is really throwing down the gauntlet. If they have the slightest inkling of true honor, it'll be dueling pistols at dawn! Brook no quarter for scoudrels.
Saw nothing new in slides from Bio Investor Forum except a more distant date for completion of Dronabinol Sleep Apnea Study. The link to NCT01755091 on ClinicalTrial.gov is http://clinicaltrials.gov/ct2/show/NCT01755091?term=dronabinol+apnea&rank=1
Noted additional studies slated to begin in December pending financing. Awaiting the "non-dilutive" financing of the December trials with anticipation, starting the trials would be a great way to end the year1
Looks like we'll have a good long wait before any trial results, but at least we have some
pros at the helm.
Seems like whenever CORX closes down on strong volume, a financing placement is announced within days. Look back to 11/10/15. Posts 39204-39211. Insiders bailing before the sale is publicly announced. How can this be FFC? It happens all the time.
Right now I also see corx NOT being a widely held biotech as a positive for the company. Just look at what's happening to those that are! Corx s.p. has already been run down the garbage disposal, and through the sewage treatment plant. Like you I can't say enough good things about this team, and that's from someone who's been anti corx since the departure of Tran.
Re: Manuso.
Some skin in the game. A refreshing change from the dark, dark Varney/Stoll days.
I like it.
10 cent s.p. before years out!
You called the bottom dude! Hope you took your own advice. I did!
Don't think the s.p. price pop will fade any time soon. We finally have
someone at the help who can run with the ball.
Joey. Congrats. Looks like you called the bottom.
Joey. Last summer was a good time to buy CORX before its short-lived run-up, maybe now is a good time to buy in anticipation of the anticipation of the February 2016 trial conclusion. Might consider selling before results are announced though. In the past all trial results good/bad/mediocre met with poor market reception. However, this is the first human trial to conclude under new management, Dr. Bow Tie, and Margolis have done it in the past, why not one more time for old times sake. Everything short of complete obliteration has already happened to this company, with only .18 cents downside why not make a small (very small) side bet with this long-shot? Would never consider talking a client into this one though!
If the slides presented are correct Dronibinol trials are set to conclude Q2 2016. When ampa drugs get back in trials is anybody's guess. IMHO this stock is a hail mary pass from Soldier Field to Three River's Stadium.
Joey. You couldn't be more correct in your estimation of this company's current market cap,
however, if management can pull a rabbit out of their hat with this cannabinol trial, they might
get enough interest to fund getting ampa drugs back in trials. Positive results from those trials would provide a s.p. differential from current levels that would far exceed chump change.
Just read the July 9th slides. Message in a bottle. Message in a bottle.
Hope sending out an S.O.S. works!
1.71 cents. Someone wanted out pretty bad today. 750K share volume so far.
Not a pretty chart.
It is my hope you get your 10 cents per share, but my fear is that food4thought is right. I'm not sure this dilution is really worth it given how trials have shaped up in the past. I'm with you on the 10 cent target, but we may need to see a fraction of a penny before we get there.
aoe. True the 3 cent price of the placement. Look at the stock chart. Before the stock was placed the 200 day M.A. of CORX was around 4.8 to 4.9 cents. Three cents being about a 38 percent discount to that price. And that was for a little more than a hundred million shares. If an investor wanted to buy a half billion shares, he'd certainly want a discount of at least the same magnitude to the current S.P. of .23. Hence my estimate of .20 cents for 1/2 billion shares seems rather generous.
My point is that CORX will need to look at avenues to fund human trials other than stock offerings.
Once the trails commence it may be that the share price will appreciate to a point where offerings will make sense, but not at current share price levels.
Unless I'm mistaken the current S.A. trial is being conducted with dronibinol. If the S.P.response to positive data with dronibinol is anything like what we got with the ampakine trials I don't see much value being created. I don't see the FDA approving any cannabinoid indications currently in trial due to it being in the same catagory as heroin. Not to mention that despite numerous trials over the last 30 years, the only way most doctors can prescribe it is if you are a patient with AIDS, or cancer undergoing chemo. The FDA has no problem with prescribing enough oxy and benzos to stop a Cape Buffalo in its tracks, so why go out on a limb with cannaboids, right?
Europe and Asia are a different story.
Re: taking it private. Jeff Margolis and Dr. Lippa certainly have the track record, contacts and resources to take CORX private, they've also been privy to information never revealed to shareholders (including the dreaded FDA letter formerly residing in Dr. Stoll's desk), so I have no doubt that if they believed it would be a profitable course of action, they'd have already embarked on a journey in that direction.
aoe. I don't think an investor willing to put up a million dollars in Corx stock would pay 3 cents a share. My guess would be more like 1.5 to 2.0 cents. If Margolis could convince a group to buy a half billion shares at 2 cents, that would raise a million (Minus legal and placement commission) for a trial, albeit a small one, tiny actually, with the hope that positive buzz from being back in clinic would increase the S.P. enough to sell more stock at a higher S.P.
But after the debacle of the last S.A. trial in England, and the disastrous dithering of the German number crunchers, I'm doubtful another small S.A. trial would generate enough positive momentum to propel the stock much above the 10 cent mark. You also have creditors and former management (no doubt more than a little peeved at having to accept small amounts of stock, and even less cash to settle their employment agreements) waiting to pounce and sell at the slightest uptick.
My guess is If they want to conduct a trial they'll have to find sources of funding other than printing/selling more stock certificates. Maybe N.I.H., or a license agreement. More loans from the Koreans. I'm sure they're looking at all options.
aoe. You were right about the numbers. I too hope we can get back in human trials. Just for fun today I put in a 16,000 share order (sounds like a lot of stock, right!) at .0237 and got it. My maximum downside on this trade is 2.37 cents per share (sounds like a small amount, because it is.)
Another half billion shares and we'll be funded for trials!
I'll be their huckleberry.
Bollix. Its R.D. that keeps me hoping.
It seems that CORX really burnt its FDA bridges with the "artifact letter" of yore, not to mention giving the whole drug category a bad name with big pharma.
Raising $$$$ is going to be really painful and expensive at .025 per share,
on the other hand we're in much better hands with Margolis and Dr. Bow Tie at the helm
than we ever were with Stoll, and Varney: the well poisoners.
One thing's for certain
If you're a believer in R.D. rescue the most you can loose is .025 cents per share!
Thanks for your research into the bump downward. All your hypos seem plausible, esp. "The General." Let's hope the money raised will be well spent on reviving R.D., and S.A.
and not one of the good doctor's rouge lab chimps chewing the face off common stockholders
to satisfy simian bloodlust.
Didn"t expect much from Dr. Greer"s presentation, but certainly wasn't prepared for this. Looks like management, or former management knows something and is acting on insider info. Same as what happened in the fall before placement of the secondary.
The SEC useless as always.
Looks like either its curtains, or a stock placement at 10-15 cents is in the works.
Anyone hear from gfp lately, or on other boards?
Thanks sparkyone for your post. I'm glad to see our September 2014 2 million share investment in Progress Scientific (Greer's Company) is paying some dividends. Hopefully mouse data will provide some fodder for more human trials with ampakines, since I know of few companies whose S.P. appreciated significantly on mouse data alone.
"Quo Vadis?" Dr. Lippa.
Delta 9 tetrahydrocannabol is the active ingredient responsible for the psychoactive effects of Cannabis. Cortext currently has dronabinol in trial for sleep apnea. Dronabinol is the generic equivalent of Marinol, approved by the FDA in 1985 for nausea and weight loss due to complications of AIDS treatment and chemotherapy. Marinol is currently marketed by Solvay Pharma. Simply put Delta 9=dronabinol=Marinol. All the same stuff. It's generic so no one pharma can own the molecule. They can license various uses, which Solvay does, and Cortex would like to do.
Many websites such as stockgumshoe.com and outsider's club hype small companies attempting to license Delta 9 for whatever ails you. They compare it to tylenol or any fill in the blanks blockbuster you can think of. Due to Marijuana's Schedule One Classification my guess is that the FDA will go slow on any expansion of Delta9/dronibinol/Marinol indications, and doctors will be very cautious with off label dispensation. As more states adopt medical/rec. use it will become less valuable to pharma rather than more.
These are my opinions. Perhaps gfp can weigh in and provide a more informed opinion.
Re: explode. Only wish it were so...
Cortex's 9 tetra compound in trial goes by Dronabinol. It's a generic CORX is putting through an NIH funded trail for sleep apnea. Marinol, which is essentially Dronabinol/9 tetra in sesame oil, is the only cannabinoid I'm aware of that has an FDA approved indication (chemo induced nausea).
Personally, I don't see how any significant pharma profits will be generated by any of these cannabinoids.
Corx needs to get ampakines back in trials, but funding is an issue. The new management's challenge is to raise money while dealing with the damage done by old management.
If you get a chance listen to this week's conference call. Goal posts keep getting moved.TSLA loses about 10K on every car they sell. They have a distribution problem (no dealership sales model illegal in many states), resale value problems due to high cost of replacement batteries, 150 cars sold in all of China last year, and BMW, Toyota, Mercedes all getting electric car religion.
On the positive side Musk is a messianic figure for many investors. Their product is truly awesome to drive (muscle car e.t.s without the guilt.)
But then so was the DeLorean.
Re: Apple. All the negatives about Apple you pointed out are true, BUT I think activists like Carl Ichan will eventually win out and force APPL to do bigger stock repurchases and maybe even dividends, so the S.P. will be bolstered by those moves in the short term. As a rule I never bet against Ichan, he makes more trading in a few seconds than I'll ever make in a lifetime.
re: gfp post #5, tsla "death cross." Sounded like Musk used the conference call to drive that death cross right through the shareholders heart. He sounded like he was one toke over the line.
The boast about besting AAPLs market cap: pure hubris. He'd be lucky to end up as a low octane Richard Branson. Wish I was short. Hope you are. Damn good call!